- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06351475
Werkzaamheid van intraoperatief gebruik van 20% albumine gecombineerd met ringerlactaat versus ringerlactaat tijdens cytoreductieve chirurgie met hyperthermische intraperitoneale chemotherapie: protocol voor een gerandomiseerde open-label klinische studie (ALBUCHIP)
Evaluatie van de werkzaamheid van de bloedvatremmer door ALBUmine Humaine 20% + Ringer Lactaat vergelijken met Ringer Lactaat Seul Chez Patiënten opereren door cytoréductie met intraperitoneale hyPerthermische CHimiothérapie
Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.
Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.
Randomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Intervention
- 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
- Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.
Outcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28
Sample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.
Discussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Jérôme Lambert, Pr
- Telefoonnummer: +33 142499742
- E-mail: jerome.lambert@u-paris.fr
Studie Contact Back-up
- Naam: Arthur Moreau, Dr
- Telefoonnummer: +33 142499394
- E-mail: arthur.moreau@aphp.fr
Studie Locaties
-
-
-
Lyon, Frankrijk
- Werving
- Hôpital Lyon Sud Pierre Bénite
-
Contact:
- Anne Li
- Telefoonnummer: +33 04 78 86 14 76
- E-mail: anne.li@chu-lyon.fr
-
Montpellier, Frankrijk
- Werving
- Institut régional du Cancer de Montpellier
-
Contact:
- Lana Zoric
- Telefoonnummer: +33 467618538
- E-mail: Lana.Zoric@icm.unicancer.fr
-
Paris, Frankrijk, 75013
- Werving
- La Pitié Salpetriere hospital
-
Contact:
- Alexandre Sitbon
- Telefoonnummer: +33 184827399
- E-mail: alexandre.sitbon@aphp.fr
-
Paris, Frankrijk
- Werving
- Lariboisière hospital
-
Contact:
- Nathalie Poirier
- Telefoonnummer: +33 1 49 95 68 43
- E-mail: nathalie.poirier@aphp.fr
-
Paris, Frankrijk
- Werving
- Saint Louis hospital
-
Contact:
- Arthur Moreau
- Telefoonnummer: +33 142499394
- E-mail: arthur.moreau@aphp.fr
-
Reims, Frankrijk
- Werving
- Robert Debré hospital
-
Contact:
- Ezechiel Bankole
- Telefoonnummer: +33 326788801
- E-mail: ebankole@chu-reims.fr
-
Strasbourg, Frankrijk
- Werving
- Hôpital Hautepierre / UIC ARMO
-
Contact:
- Valentina FAITOT
- Telefoonnummer: +33 388116768
- E-mail: valentina.faitot@chru-strasbourg.fr
-
Villejuif, Frankrijk
- Werving
- Gustave Roussy Institute
-
Contact:
- Stéphanie Suria
- Telefoonnummer: +33 142114437
- E-mail: Stephanie.SURIA@gustaveroussy.fr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male and female patients aged 18 years old and older
- Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
- Patient volunteer for the study and provided written informed consent
- Patient affiliated to the French Health Insurance
Exclusion Criteria:
- Adults >75 years old
- Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG > 2 or Karnofsky index < 75)
- Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
- Severe preoperative hypoalbuminemia (albuminemia < 20 g/L)
- History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction < 40%)
- Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
- Significant ascites with preoperative respiratory repercussions
- Uncontrolled diabetes (HbA1c > 8.5%)
- Allergy to exogenous human albumin and its excipients.
- Contraindication to the administration of Ringer's lactate (history of allergy)
- Hyperkalemia > 6.0 mmol/L
- Hypercalcemia (total calcium > 2.60 mmol/L)
- Chronic use of digitalis and hyperkalemic diuretics
- Pregnancy, breastfeeding
- Known preoperative renal failure (GFR < 30 mL/min/1.73m2 or extrarenal purification)
- Recent brain trauma < 6 months (traumatic, ischemic, or hemorrhagic)
- Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
- Patient deprived of liberty
- Patient under guardianship or curatorship
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: 20% Albumin + Ringer Lactate group
Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
|
Actieve vergelijker: Control group
Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned. |
Ringer lactate |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Comprehensive Complication Index score
Tijdsspanne: At day 28
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 28
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Volume van intra-operatieve en postoperatieve vloeistoftherapie
Tijdsspanne: 48 uur na de operatie
|
48 uur na de operatie
|
|
|
Cumulatieve incidentie van chirurgische postoperatieve complicaties
Tijdsspanne: Tot dag 28
|
Tot dag 28
|
|
|
Aantal dagen in leven buiten de intensive care
Tijdsspanne: Tot dag 28
|
Tot dag 28
|
|
|
Aantal dagen levend buiten het ziekenhuis
Tijdsspanne: Tot dag 28
|
Tot dag 28
|
|
|
Incidentie van infectieuze complicaties
Tijdsspanne: Tot dag 28
|
Tot dag 28
|
|
|
Incidentie van medische complicaties
Tijdsspanne: Tot dag 28
|
Tot dag 28
|
|
|
Cumulatieve incidentie van overlijden op de intensive care
Tijdsspanne: Tot dag 28
|
Tot dag 28
|
|
|
Cumulatieve incidentie van overlijden in het ziekenhuis
Tijdsspanne: Tot dag 28
|
Tot dag 28
|
|
|
Aantal dagen onder vasopressoren
Tijdsspanne: Tot en met dag 28
|
Tot en met dag 28
|
|
|
Aandeel van patiënten met allergische complicaties aan albumine
Tijdsspanne: Op dag 133
|
Op dag 133
|
|
|
Comprehensive Complication Index score
Tijdsspanne: At day 7
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 7
|
|
Number of days under mechanical ventilation outside the operating room
Tijdsspanne: Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Number of days under renal replacement therapy
Tijdsspanne: Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Sequential organ failure assessment (SOFA) score variation
Tijdsspanne: 48 hours after surgery
|
Between pre operative period and 48h after surgery |
48 hours after surgery
|
|
SOFA score
Tijdsspanne: At day 28
|
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function |
At day 28
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- APHP230864
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .